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OBJECTIVES This study was performed to evaluate whether or not the simpler case identification and data
abstraction processes used in National Registry of Myocardial Infarction two (NRMI 2) are
comparable with the more rigorous processes utilized in the Cooperative Cardiovascular
Project (CCP).
BACKGROUND The increased demand for quality of care and outcomes data in hospitalized patients has
resulted in a proliferation of databases of varying quality. For patients admitted with
myocardial infarction, there are two national databases that attempt to capture critical process
and outcome data using different case identification and abstraction processes.
METHODS We compared case ascertainment and data elements collected in Medicare-eligible patients
included in the industry-sponsored NRMI 2 with Medicare enrollees included in the Health
Care Financing Administration-sponsored CCP who were admitted during identical enroll-
ment periods. Internal and external validity of NRMI 2 was defined using the CCP as the
“gold standard.”
RESULTS Demographic and procedure use data obtained independently in each database were nearly
identical. There was a tendency for NRMI 2 to identify past medical histories such as prior
infarct (29% vs. 31%, p , 0.001) or heart failure (21% vs. 25%, p , 0.001) less frequently
than the CCP. Hospital mortality was calculated to be higher in NRMI 2 (19.7% vs. 18.1%,
p , 0.001) due mostly to the inclusion of noninsured patients 65 years and older in
NRMI 2.
CONCLUSIONS We conclude that the simpler case ascertainment and data collection strategies employed by
NRMI 2 result in process and outcome measures that are comparable to the more rigorous
methods utilized by the CCP. Outcomes that are more difficult to measure from retrospective
chart review such as stroke and recurrent myocardial infarction must be interpreted cautiously.
(J Am Coll Cardiol 1999;33:1886–94) © 1999 by the American College of Cardiology
There is an increased demand by organizations such as
payors, healthcare systems, accreditation agencies as well as
the public for data on patient outcomes (1–5). Many of
these organizations have launched initiatives to collect
patient-level process and outcome data. In patients with
cardiovascular disease, database research has resulted in
effectiveness evaluations of drugs (6), medical procedures
(6,7) and processes of care (8–10). Examples of cardiovas-
cular databases range from administrative datasets such as
Medicare’s MEDPAR database (11–15), which provides
diagnoses, treatments and hospital mortality to clinically
rich databases collected as part of randomized trials (16–
18). Between these extremes, there are a large number of
database models of various scope and quality. The quality of
the methods utilized for data collection and analysis is
becoming increasingly important because external review
organizations as well as the public use these data to evaluate
quality of care. Public release of results obtained from
studies utilizing Medicare claims data has resulted in both
hospital and practitioner identification as providing worse
than expected outcomes (19–22).
From the *Northwest Health Services Research and Development Program, Puget
Sound VA Healthcare System, Seattle, Washington; †University of Washington,
Seattle, Washington; ‡Nuffield Institute for Health, Leeds, United Kingdom;
§PRO-West, Seattle, Washington; \Genentech Inc., South San Francisco, Califor-
nia; and ¶University of California, San Francisco, San Francisco, California. Per-
formed as a Quality Assurance Project in conjunction with ProWest and the
Healthcare Financing Administration. This study was supported by grant 94-304,
VHA Health Services Research Career Development Award and grant 638309 from
the Health Care Financing Administration and was developed as a part of a quality
improvement project conducted under the Health Care Quality Improvement
Program of the Health Care Financing Administration, Baltimore, Maryland. The
conclusions and opinions expressed and the methods used are those of the authors and
not necessarily the policy of the Health Care Financing Administration. The authors
assume all responsibility for accuracy and completeness.
Manuscript received June 22, 1998; revised manuscript received January 27, 1999,
accepted February 8, 1999.
Journal of the American College of Cardiology Vol. 33, No. 7, 1999
© 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00
Published by Elsevier Science Inc. PII S0735-1097(99)00113-8
Patients presenting with acute myocardial infarction
(AMI) have been widely studied in various databases due to
the large number of cases, the public health threat and the
availability of a variety of effective treatments. Although
there are many administrative and regional databases that
include AMI patients, there are only two with large national
samples collected outside clinical trials: the Health Care
Financing Administrative (HCFA) database, the Coopera-
tive Cardiovascular Project (CCP) (23) and the pharmaceu-
tical industry-sponsored National Registry of Myocardial
Infarction (NRMI 2) (24–26).
These two large datasets attempted to capture informa-
tion on the same patient populations in many of the same
hospitals using markedly different case ascertainment and
data collection strategies. The CCP utilized a centralized
case identification and internally validated abstraction strat-
egy, whereas NRMI 2 utilizes a local strategy with simpler
data collection forms. Although the centralized strategy
should result in better case ascertainment and potentially
more accurate data collection, the NRMI 2 methods have
the advantage of being less expensive, which facilitates
ongoing data collection with rapid feedback of results to
practitioners. The purpose of the present study was to
compare these two datasets to evaluate whether or not the
two strategies resulted in similar findings in AMI patients.
Specifically, we asked the study question whether or not the
simpler case identification and data abstraction processes
used by NRMI 2 were comparable with the more rigorous
processes utilized in the CCP.
METHODS
Databases. The National Registry of Myocardial Infarc-
tion 2 is a multi-center voluntary database designed to
collect, analyze and report cross-sectional data on patients
admitted with myocardial infarction throughout the U.S.
(24). The purpose of NRMI 2 is to provide participating
hospitals with periodic summary data assisting local contin-
uous quality assessment activities, to aggregate and test
hypotheses describing AMI populations and to monitor the
safety experience of a particular thrombolytic agent, alte-
plase. Between June 1994 and January 1997, 1,529 hospitals
enrolled 446,970 patients into NRMI 2.
Data collection in NRMI 2 depends on local patient
identification and chart abstraction in combination with
centralized data entry. A study coordinator at each hospital
is instructed to enroll consecutive confirmed infarcts utiliz-
ing local AMI criteria, which commonly includes ECG,
cardiac enzyme or angiographic abnormalities or a discharge
diagnosis of 410.xx electrocardiogram (acute myocardial
infarction by ICD coding). Coordinators attend a half-day
training course and are provided with a reference manual
that includes case report form field definitions and examples
of correct responses. Patient information is transcribed onto
a two-page case report form. Completed forms are for-
warded to an independent central data collection center,
ClinTrials Research, Inc. (Lexington, Kentucky). There are
87 electronic data checks to detect internal inconsistencies,
omissions and out-of-range values. Case report forms that
fail edit checks are mailed back to the study coordinator for
data resolution.
The Cooperative Cardiovascular Project database is a
national effort by the HCFA to improve care for Medicare
beneficiaries discharged with AMI. Unlike NRMI 2, the
CCP is a mandated quality improvement process and is
therefore included in the universe of hospitals providing care
for Medicare beneficiaries with AMI.
Patients with the discharge diagnosis of AMI (410.xx,
excluding 410.x2 [re-admission for AMI within eight weeks
of discharge]) were retrospectively identified by HCFA
utilizing a central administrative database (23). All hospitals
that admitted patients with Medicare insurance were then
required to submit the photocopied medical records of the
identified AMI patients to a central data abstraction center.
Acute-care hospitals from across the country (n 5 4,223)
submitted 224,377 medical records for AMI patients dis-
charged within specified eight-month periods between Feb-
ruary, 1994 and July, 1995. Clinical Data Abstraction
Centers (CDACs) performed data abstraction from medical
records.
All CDAC abstractors receive substantial training in
applicable medical terms and procedures. In addition,
CDACs periodically perform blinded reabstractions on
random samples of medical records to measure the quality of
the abstraction process. Thus, in comparison with NRMI 2,
the CCP is a database that utilized centralized case identi-
fication and data abstraction.
Database comparison. Internal validity was evaluated at
the hospital and patient level. To evaluate case ascertain-
ment and overall comparability of the databases indepen-
dent of individual patient matching, we performed a
hospital-level comparison. In this comparison we attempted
to evaluate whether or not differences in patient identifica-
tion procedures would result in differences in baseline
demographic, patient presentation, process of care and
outcome calculated in each database. For comparison pur-
poses, the CCP was designated to be the reference database.
Because there were hospitals in NRMI 2 not included in
the CCP and vice versa, hospitals were first matched based
on Medicare provider number. Patients discharged from
hospitals not participating in both databases were excluded.
Next, a set of discharge dates common to both databases
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CCP 5 Cooperative Cardiovascular Project
CDAC 5 Clinical Data Abstraction Centers
HCFA 5 Health Care Financing Administration
NRMI 2 5 National Registry of Myocardial Infarction
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was defined for each hospital and patients discharged
outside these inclusive dates were excluded. To define a
patient population that should have been Medicare-eligible,
we excluded patients 64 years or younger. Finally, because
NRMI 2 does not include unique patient identifiers that
allow linking medical records in those patients who were
transferred, patients who were either transferred in or
transferred out of the index hospital were excluded from the
analysis. Using this process, we identified 35,675 patients in
NRMI 2 and 42,703 patients in the CCP that were
admitted to 1,087 matching hospitals during identical
enrollment periods.
To evaluate internal validity at the individual patient
level, we performed a patient-level analysis. In this analysis,
individual patients enrolled in both databases were matched,
and common variables collected in both databases were
compared. Patient matching was based on composite keys
that were developed based on shared attributes within the
data schema. The composite keys were classified into a
4-key (hospital, discharge date, age and gender), 5-key
(4-key plus arrival date) and 6-key (5-key plus arrival time).
To match records among the CCP and NRMI 2 compar-
ison populations, an iterative program module was devel-
oped to identify 6-key, 5-key and 4-key matches. When all
attributes within the key were the same between NRMI 2
and CCP comparison populations, the match was consid-
ered exact. Discharge and arrival date were permitted an
allowance of 61 day, age 61 year and arrival time 61 h.
The highest priority patient match occurred at the 6-key
level.
The preliminary patient-level database contained 28,689
records in which 24,908 (87%) were exact matches. Among
the exact matches, 14,531 (58%) were based on the 6-key
match, 9,940 (40%) on 5-key and 437 (2%) on 4-key. There
were also 3,025 duplicate cases removed from the prelimi-
nary match resulting in a final matched NRMI 2/CCP
comparison population of 25,664 patient episodes contrib-
uted by 1,076 hospitals.
External validity was evaluated by comparing baseline
data, process and outcome of care in all patients 65 years and
older in NRMI 2 and CCP without matching at either the
patient or hospital-level (unmatched comparison). For this
comparison, there were 73,774 patients admitted to 1,338
hospitals that participated in NRMI 2 and 129,482 patients
admitted to 4,205 hospitals in the CCP.
Data analysis. In the hospital-level and unmatched com-
parison, baseline demographics, clinical events, use of med-
ications, utilization of cardiac procedures and outcomes
were compared using chi-square for categorical and Student
t test for continuous variable comparisons. Variables chosen
for comparison were those included in both databases and
were predefined based on previous studies evaluating out-
come in AMI patients. Logistic regression was utilized to
determine the multivariate association between the variables
and in-hospital mortality in each database to compare
whether the calculated odds ratios were different depending
on the database. All statistical calculations were performed
with the SAS 6.12 statistical procedure (SAS Institute).
In the patient-level comparison, percent agreement and
Kappa scores were calculated for variables collected in each
dataset. Percent of agreement was defined as the proportion
of agreement plus the proportion of those who did not agree
divided by the total number of matched patients.
RESULTS
There were a total of 446,970 patients included in the
NRMI 2 database and 224,377 in the CCP database. From
these sources, we identified 35,675 AMI patients in NRMI
2 and 42,703 patients in CCP who were likely to be
Medicare-eligible and who were admitted to the same
hospitals during the same data abstraction period. From
these two groups, we were able to match 25,664 patients
that represented identical patients enrolled in both data-
bases and are referred to as the patient-level comparison.
Patients included in the CCP but not identified in NRMI
2 (CCP unmatched) (Table 1) were similar to the entire
CCP cohort. There were no substantial differences in
demographics, past medical histories or hospital course.
Hospital mortality was slightly higher in CCP patients not
identified in NRMI 2 (18.7% vs. 18.1%, p 5 0.08). Patients
included in NRMI 2 but not identified in the CCP (NRMI
2 unmatched) were similar to the entire NRMI 2 cohort in
terms of demographics and past medical history. However,
hospital complications including shock (8.3% vs. 7.8%, p 5
0.09), stroke (2.3% vs. 1.9%, p 5 0.008) and hospital
mortality (24.1% vs. 19.7%, p 5 0.001) were each higher in
the NRMI 2 patients not identified in the CCP.
Hospital-level comparison. In the first analysis, we com-
pared selected variables reported in hospitals included in
both databases during matched time periods (hospital-level
comparison in which there was no individual patient match-
ing). Baseline demographic data and past medical histories
were similar in the two databases (Table 2). Although there
were statistically significant differences in most comparisons
due to the large numbers of patients in each cohort, there
was little difference in age, gender or race. In general, the
CCP database was more likely to identify past diseases such
as prior myocardial infarction or heart failure. There was
little difference in the identification of past cardiac proce-
dures.
Process of care variables were identified with similar
frequency in each database (Table 3). National Registry of
Myocardial Infarction 2 was more likely to identify the use
of thrombolytic therapy in AMI patients (15.6% vs. 14.6%,
p , 0.001), but there was little difference in the identifica-
tion of the use of cardiac catheterization, bypass surgery or
coronary angioplasty. Identification of discharge medica-
tions was similar in both databases, although the CCP was
somewhat more likely to identify the use of aspirin,
angiotension-converting enzyme inhibitors and beta-
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adrenergic blocking agents at hospital discharge. The mean
length-of-hospital stay was nearly identical.
After hospital admission, NRMI 2 was less likely to
identify hospital complications such as shock (7.8% vs.
8.3%, p 5 0.025) or stroke (1.9% vs. 3.4%, p , 0.001)
(Table 3). Most stroke identification in NRMI 2 was in
patients with intracranial bleeding (1.6%); thus, there ap-
peared to be underidentification of nonhemorrhagic strokes
in NRMI 2. Hospital mortality was higher in NRMI 2
(19.7% vs. 18.1%, p , 0.001). This may be explained by the
inclusion of noninsured elderly patients (although within
the Medicare age group eligibility) in NRMI 2 that ap-
peared to have higher mortality than those identified with
Medicare insurance (24.5% vs. 19.9%, p 5 0.06).
Table 1. Comparison of Matched and Unmatched Patients
CCP Cohort
(n 5 42,703)
CCP
Unmatched
(n 5 17,039)
NRMI 2
Cohort
(n 5 35,675)
NRMI 2
Unmatched
(n 5 10,011)
Men (%) 49.4 48.4 50.3 50.8
White (%) 89.5 88.6 86.9 82.8
Age
(mean 6 SD) 77.3 6 7.5 77.6 6 7.6 76.9 6 7.5 76.5 6 7.6
Medicare (%) 100% 100% 80% 64%
H/O
MI (%) 32.0 32.9 30.0 29.1
CHF (%) 25.1 26.9 21.3 22.7
CABG (%) 12.9 12.5 12.6 11.8
PTCA (%) 6.7 6.6 5.3 5.2
CVA (%) 15.7 15.8 11.7 11.4
Thrombolytic (%) 14.6 10.9 15.6 11.1
Procedures
Caths (%) 32.8 30.3 33.3 29.6
PTCA (%) 12.5 10.9 12.6 11.3
CABG (%) 7.0 7.1 7.1 7.9
Clinical Events
CVA (%) 3.4 3.9 1.9 2.3
Shock (%) 8.3 8.3 7.8 8.3
Re-MI (%) 3.3 3.1 2.9 3.3
CHF (%) 48.1 50.1 24.7 26.7
Hospital mortality (%) 18.13 18.75 19.7 24.15
1 year (%) 36.8 38.8
CABG 5 coronary artery bypass grafting; CCP 5 Cooperative Cardiovascular Project; CHF 5 congestive heart failure; CVA 5
cerebrovascular accident; H/O 5 history of; MI 5 myocardial infarction; NRMI 5 National Registry of Myocardial Infarction;
PTCA 5 percutaneous transluminal coronary angioplasty.
Table 2. Hospital-Level Comparison—Baseline Characteristics
NRMI
(n 5 35,675)
CCP
(n 5 42,703) p Value
Age (mean) 76.9 77.3 0.391
Gender (% male) 50.3 49.4 0.015
White (%) 86.9 89.5 , 0.001
H/O Myocardial
infarction (%)
29.0 32.0 , 0.001
H/O Heart failure (%) 21.3 25.1 , 0.001
H/O Bypass surgery (%) 12.2 12.9 0.002
H/O Coronary
angioplasty (%)
5.3 6.7 , 0.001
Abbreviations as in Table 1.
Table 3. Hospital-Level Comparison—Process of Care
and Outcome
NRMI
(n 5 35,675)
CCP
(n 5 42,703)
p
Value
Length of stay (mean) 8.33 8.11 , 0.001
Cardiac catheterization
(%)
33.3 32.8 0.156
Coronary angioplasty (%) 12.6 12.5 0.846
Bypass surgery (%) 7.1 7.0 0.420
Thrombolytic therapy
(%)
15.6 14.6 , 0.001
Aspirin at discharge (%)* 64.5 65.3 0.044
Ace inhibitors at
discharge (%)*
30.4 35.4 , 0.001
Beta-blocker at discharge
(%)*
35.6 38.1 , 0.001
Mortality (%) 19.7 18.1 , 0.001
All stroke (%) 1.9 3.4 , 0.001
Intracranial bleeding (%) 1.6 Not collected NA
Shock (%) 7.8 8.3 0.025
*Excludes deaths ([NRMI, n 5 28,658] [CCP, n 5 34,958]). Abbreviations as in
Table 1.
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To further illustrate the comparability of the two datasets
using the hospital-level comparison (e.g., without individual
patient matching) we constructed two logistic regression
models that evaluated the association between variables
common to both datasets and hospital death. Each model
was run first in the CCP cohort and then in the NRMI 2
cohort. Using a set of predefined variables, each database
model predicted a similar association between the variable
and hospital death (Fig. 1). For example, the association
between age and hospital death was (odds ratio 5 1.18 vs.
1.25 per year for NRMI 2 and the CCP model, respective-
ly). There was less correlation with the variables of reinfarc-
tion and shock (odds ratio 5 5.90 vs. 2.98 [reinfarction] and
odds ratio 5 33.85 vs. 23.18 [shock] for NRMI 2 and the
CCP model, respectively). In a second model, we added
variables included in CCP that were not abstracted in
NRMI 2. In this expanded model, the CCP variables terminal
illness (odds ratio 5 1.6, 95%, confidence interval 5 1.1–2.1)
and apache 2 score (odds ratio 5 1.12, 95%, confidence
interval 5 1.11–1.13) were significantly associated with hos-
pital mortality. The history of dementia or COPD were not
associated with hospital mortality. The odds ratios illustrated
in Figure 1 did not substantially change when these additional
variables were added to the model.
Figure 1. The association between key variables collected in both the CCP and NRMI 2 and hospital death. Odds ratios and 95%
confidence intervals were calculated independently in each database using patients included in the hospital-level comparison. Although
there was no individual patient matching, the odds of death calculated for each variable in each cohort were similar.
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Patient-level comparison. To compare data quality at the
patient level, we performed an analysis that compared
individual variables collected in both databases on 25,664
matched patients. Because patients were matched by both
age and gender, there was nearly 100% agreement on these
variables (Table 4). However, there was also good agree-
ment in most other demographic and historic variables
collected in both databases (kappa values 5 0.61–0.99).
Consistent with the hospital-level comparison, prior history
variables such as prior infarct (88% agreement) or heart
failure (87% agreement) were somewhat underascertained in
NRMI 2. Process of care variables such as procedure use
(cardiac catheterization—98%, bypass surgery—100% and
coronary angioplasty—98%), thrombolytic therapy use
(98%) and discharge medications showed high levels of
agreement (Table 5, kappa values 5 0.75–0.97). There was
close agreement on the hospital mortality end point (kap-
pa 5 0.98). One-hundred ten patients were classified as
hospital deaths in NRMI 2 but classified as alive in the
CCP, whereas 60 patients were classified as hospital deaths
in the CCP but classified as alive in NRMI 2 (Table 6). Of
clinical end points, identification of reinfarction had the
lowest kappa value (0.21) with disagreement in 1,222 of
25,664 patients.
External validity. Because the CCP included all non-
Federal hospitals (n 5 4,223) while NRMI 2 (n 5 1,338)
included select hospitals, we compared Medicare eligible
patients in each database without matching at either the
hospital or patient level to evaluate external validity. Hos-
pitals participating in NRMI 2 were larger on average (264
vs. 174 beds, p 5 0.0001), more likely to have on-site
catheterization facilities (72.6% vs. 42.9%, p 5 0.001) and
on-site bypass surgery (39.3 vs. 20.3, p 5 0.001). Despite
these differences in hospital characteristics, most demo-
graphic, process and outcome data were similar (Table 7).
As with the other analyses, past histories were modestly
underreported in NRMI 2 with the greatest difference noted
in past history of stroke (12.0% in NRMI 2 vs. 15.5% in
CCP, p 5 0.001). Patients included in NRMI 2 were more
likely to undergo thrombolysis, cardiac catheterization, cor-
onary angioplasty or bypass surgery. Clinical event reporting
was similar except for underreporting of stroke (2% vs.
3.5%, p 5 0.001) and heart failure complication (24.7% vs.
47.8%, p 5 0.001) in NRMI 2. Hospital mortality was
similar in the two databases.
DISCUSSION
The demand for process and outcome measures in Ameri-
can healthcare systems is growing. The traditional mecha-
nism for obtaining these measures has been the administra-
tive dataset, which has the advantage of identifying all
patients with a particular diagnosis or procedure (11–15).
The disadvantage of administrative data is the lack of
Table 4. Patient-Level Comparison—Baseline Characteristics
% Agreement
(n 5 25,664) Kappa
White 94.5 0.71
Gender 100.0 1.00
Age 99.8 0.99
H/O Myocardial infarction 87.5 0.70
H/O Congestive heart failure 86.6 0.61
Abbreviations as in Table 1.
Table 5. Patient-Level Comparison—Hospital Course
and Medications
% Agreement
(n 5 25,664) Kappa
Stroke in hospital 98.0 0.57
Reinfarction 95.2 0.21
Shock in hospital 94.7 0.63
Thrombolytic treatment 98.3 0.94
Coronary angiography 98.2 0.96
Coronary angioplasty 97.9 0.91
Bypass surgery 99.7 0.97
Aspirin at discharge 89.1 0.75
Beta-blocker at discharge 91.6 0.82
ACE inhibitor at
discharge
89.6 0.77
Hospital mortality 99.3 0.98
Table 6. Patient-Level Comparison—In-Hospital Mortality
NRMI: Yes NRMI: No
CCP: yes 4,489 60
CCP: no 110 21,005
Kappa 5 0.98. Abbreviations as in Table 1.
Table 7. External Validity Comparison
NRMI
(n 5 73,774)
CCP
(n 5 129,482)
p
Value
Number hospitals 1138 4223
Age (mean) 77.0 77.6 0.001
Gender (% male) 50.3 48.9 0.001
White (%) 86.7 88.0 0.001
H/O Myocardial
infarction (%)
29.1 31.8 0.001
H/O Heart failure (%) 21.3 25.6 0.001
H/O Stroke (%) 12.0 15.5 0.001
H/O Bypass surgery (%) 12.4 12.6 0.186
Cardiac catheterization (%) 34.4 28.4 0.001
Coronary angioplasty (%) 13.3 11.0 0.001
Bypass surgery (%) 7.6 5.9 0.001
Thrombolytic therapy (%) 15.7 13.1 0.001
Heart failure complication
(%)
24.7 47.8 0.001
Stroke complication (%) 2.0 3.5 0.001
Hospital death (%) 19.5 18.8 0.001
Abbreviations as in Table 1.
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clinical detail (27). At the other extreme are databases that
are obtained in the setting of clinical trials which have the
advantage of clinical detail and accuracy but are resource-
intensive and limited to the select patient population that
qualifies for the trial (16–18). The challenge for physicians,
researchers and administrators interested in measuring pro-
cess of care and outcome is to develop efficient mechanisms
to identify patients and collect data that are both internally
and externally valid.
In this study, we compared two different mechanisms to
collect process and outcome data in patients with AMI. The
CCP database relies on a centralized system of patient
identification and data abstraction that assures accuracy
through standardized data abstraction procedures and ran-
dom reabstraction methods. Although this methodology
should be considered the “gold standard,” it is time intensive
and therefore expensive and does not lend itself to contin-
uous data collection. The NRMI 2 database, on the other
hand, relies on local hospital patient identification and chart
abstraction without methods for assuring consecutive pa-
tient enrollment or chart reabstraction for purposes of
validation. This data collection process is less time intensive
and therefore can be used as an ongoing registry. However,
the less rigorous data collection methodology used in
NRMI 2 has led some to question the validity of findings.
For example, if hospitals excluded patients with poor
outcomes or processes of care, this would bias overall results
reported from the NRMI 2 database.
Findings. Our findings, however, confirmed few differ-
ences in these two datasets despite the substantial difference
in data collection methodologies. Although there was a
modest underascertainment of potentially eligible infarct
cases (10%–15%), NRMI 2 was comparable with the CCP
in defining demographic data, past medical histories and
procedure and medication use. Surprisingly, overall mortal-
ity in the hospital-level comparison was somewhat higher in
NRMI 2 than the CCP database. We had hypothesized
that NRMI 2 investigators may underreport poor outcomes,
but this did not seem to be the case. It appears that the
higher mortality calculated in NRMI 2 patients was due to
inclusion of non-Medicare insured patients in NRMI 2
which would not have been identified in the CCP. In fact,
in 25,664 matched patients, there was disagreement in the
mortality end point in only 0.2%.
Of some concern is a higher level of disagreement (lower
kappa values) at the patient-level analysis in other clinical
end points such as shock, stroke or recurrent infarction. One
explanation for these findings could be different variable
definitions used in each database. For example, NRMI 2
defines recurrent myocardial infarction as “the occurrence of
another MI confirmed by new diagnostic ST/T wave
changes or a second elevation of cardiac enzymes .2 times
normal.” The CCP, on the other hand, defines the same
variable as “a new event during the hospitalization in which
more heart muscle is damaged.” Clinicians may also use
different definitions for these events that may lead to
variation in chart documentation. Because of the lower
kappa values, these outcomes (shock, stroke and recurrent
infarction) must be viewed with caution.
The external validity of NRMI 2 was also reasonable as
compared with the CCP. Data obtained from NRMI 2
would underidentify comorbidities and overidentify cardiac
procedure use as compared with the population as a whole.
These differences were quite small and probably not clini-
cally meaningful. Although mortality outcomes were simi-
lar, the rate of stroke and heart failure during the hospital-
ization was substantially different between databases.
Although not tested in this study, we might speculate
why the results obtained from NRMI 2 were comparable
with the more rigorous CCP database. First, identification
of AMI patients is relatively simple, because nearly all
patients are treated in the hospital, most are admitted to one
area of the hospital (CCU) and there is a financial incentive
to code with the AMI discharge diagnosis (410). Second,
experience with NRMI 1 gave the study sponsors and
advisors valuable information on the design and use of the
NRMI 2 data collection form (24,28). This allowed the data
collection form to include most critical data while being
efficient and “user-friendly” to complete. Third, many hos-
pitals participating in NRMI 2 use the quarterly report
describing individual hospital results in comparison with
National standards, as an internal quality assurance mech-
anism. This may promote careful patient identification and
chart abstraction in those institutions. Finally, hospitals
receive a modest payment for each case report form that is
completed, which may promote participation by institutions
with limited resources.
Study limitations. Although these two independently col-
lected databases were comparable, there are several limita-
tions of the study. First, AMI is probably a simpler disease
to study in a registry such as NRMI 2 due to the hospital-
ization of most patients and readily measured process and
outcome variables. Our findings are not easily generalized to
other diseases. Second, the incentives for quality data
collection in NRMI 2, such as the use of quarterly reports
for quality improvement projects, are likely critical compo-
nents of the validity of the Registry. Our findings are
probably not easily generalized to other registries with
different procedures and incentives to assure data quality.
Finally, although we assumed that costs for NRMI 2 were
lower than CCP based on time of chart abstraction and the
absence of chart copying and mailing to a central data
collection center, we were unable to measure costs directly.
We also compared two databases that relied on retrospec-
tive chart abstraction to define variables. Although we
defined the CCP as the “gold standard,” chart abstraction
may not be the optimal method for defining process and
outcome of care. For some healthcare systems, electronic
medical records with point of care prospective data collec-
tion using standardized data definitions have replaced paper
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charts and are considered by some to be the optimal data
collection method. Although we could not compare either
the CCP or NRMI 2 with an electronic medical record, the
paper chart is still used in the majority of U.S. hospitals and
thus represents the best available record of process and
outcome of care.
Implications. The findings from this study have important
policy implications regarding national and regional efforts to
assess and improve care among patients with AMI. The
CCP, which had the advantage of including the universe of
Medicare beneficiaries discharged from hospitals in a spe-
cific time period, required a substantially greater commit-
ment of resources than the approach taken with NRMI 2.
That is, hundreds of thousands of medical records were
photocopied and submitted to a central site, and medical
records were abstracted by reviewers not familiar with each
facility’s records and conventions. Hospital records of non-
Medicare beneficiaries were not included. In addition,
considerable time—often two years or more—elapsed be-
tween the delivery of care and reporting of the data back to
hospitals, and only aggregate data are reported.
In contrast, the NRMI 2 data were efficiently abstracted
from the original medical records, returned to hospitals on
a quarterly basis with local and national comparisons and
included patients discharged with AMI regardless of pay-
ment source. The timeliness, continuous feedback and
involvement of local care providers in NRMI 2 data collec-
tion and analysis are all characteristics recognized to facili-
tate quality improvement activities.
The efficiencies gained through the NRMI 2 data collec-
tion process result in some limitations of the Registry. First
is the underascertainment of eligible patients with AMI. It
is unlikely that this underascertainment has a major influ-
ence on the use of the Registry as either a research tool or
a quality improvement instrument. This is because AMI
patients excluded from NRMI 2 appear to be similar to
those included in the database and would be an unlikely
source of bias. A second limitation of NRMI 2 is disagree-
ment at the individual patient level about the occurrence of
clinical events such as stroke or recurrent infarction. Because
we did not observe substantial differences in this variable at
the hospital-level analyses, it is unlikely that misclassifica-
tion would influence research results based on NRMI 2
data. As a quality assurance tool, misclassification of sentinel
events in NRMI 2 could be problematic. However, because
hospitals collect and interpret their own data, validation of
data at the patient level is under direct control of those
receiving the quality reports. For institutions using NRMI 2
as an internal quality assurance process, it is critical to insure
adequate training of local abstractors. Institutions might
also consider random reabstraction of charts to insure data
reliability. Finally, the local case identification and chart
abstraction processes along with patient confidentiality is-
sues do not allow NRMI 2 to determine outcome in patients
after hospital transfer and after discharge. Partnerships with
other administrative datasets may allow these linkages to
take place in the future.
Conclusions. We conclude that the simpler case ascertain-
ment and data collection strategies employed by NRMI 2
result in process and outcome measures that are comparable
with the more rigorous methods utilized by the CCP.
Outcomes that are more difficult to measure from retrospec-
tive chart review such as stroke and recurrent myocardial
infarction must be interpreted cautiously.
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